Clinical Research Office. A partnership between Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield

Interstitial Lung Disease

The Sheffield Interstitial Lung Disease (ILD) Service is a regionally/nationally commissioned service serving the population of Sheffield and South Yorkshire, although we also see patients from further afield. As of March 2023 there are 6 ILD consultants and 2.2 WTE (whole time equivalent) Respiratory Specialist Nurses, along with a multi-professional group of dedicated staff including radiologists, thoracic surgeons and pathologists. We provide diagnostics and treatment as well as being active in clinical trials exploring new treatments and pathways of care.

Further information about ILD is available at the British Lung Foundation website (

The ILD service is research active. We participate in a number of diverse studies including investigation of new medications and treatments as well as collaborating with local and national colleagues exploring improved pathways of care. We work with a specialist group of research nurses from the Sheffield Teaching Hospitals Clinical Research Facility who coordinate and deliver research projects in an experienced and efficient way. We encourage all our eligible patients to become involved in research if they wish, in line with national guidelines, although if you do not wish to be involved this will not alter your clinical care in any way.

Some of our current ILD research studies are:

TIPAL - The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial.

Principal Investigator: Dr Nicholas Weatherley

 Study Details: This study plans to recruit 298 participants with   idiopathic  pulmonary fibrosis from different regions of the UK. The     study   is aiming to find out whether lansoprazole, when given alongside   current   treatments, slows down the decline in lung function which is  associated   with idiopathic pulmonary fibrosis.